New combo therapy shows promise for blinding eye condition
NCT ID NCT03941587
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two treatments for polypoidal choroidal vasculopathy (PCV), an eye disease that can lead to blindness. Sixty patients received either eye injections of aflibercept alone or aflibercept combined with a special light therapy (reduced-fluence PDT). The goal was to see which approach better closed abnormal blood vessels and improved vision over 12 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POLYPOIDAL CHOROIDAL VASCULOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National University Hospital
Singapore, Singapore
-
Singapore National Eye Centre
Singapore, Singapore, 168751, Singapore
More trials for these conditions
Other studies related to the condition(s) this trial covers.